Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Chenodiol

FDA-approved product (tablet, oral), marketed as Chenix, Chenodiol, Ctexli.

Registered studies
30
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Chenodiol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cerebrotendinous xanthomatosis
  • Inborn errors of metabolism

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Bile acids and derivatives
FDA pharmacologic class
Bile Acid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA69.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis31.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

30registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Chenodiol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Chenodiol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).

    NCT07005752 · start 2025-07-28

    Registered record
    Registry ID
    NCT07005752
    Conditions
    Cholesterol Cholelithiasis
    Interventions
    CnU cap. 250mg & Ursa placebo tab. 200mg; Ursa tab. 200mg & CnU placebo cap. 250mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-07-28
    Completion
    2028-06-13
    Enrolment
    484

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholesterol Cholelithiasis
    InterventionCnU cap. 250mg & Ursa placebo tab. 200mg; Ursa tab. 200mg & CnU placebo cap. 250mg
    PhasePhase 4
    Registry statusRecruiting

  • A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)

    NCT06260748 · start 2024-05-27

    Registered record
    Registry ID
    NCT06260748
    Conditions
    Cerebrotendinous Xanthomatoses
    Interventions
    Chenodeoxycholic acid; Chenodeoxycholic acid Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2024-05-27
    Completion
    2025-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebrotendinous Xanthomatoses
    InterventionChenodeoxycholic acid; Chenodeoxycholic acid Placebo
    PhasePhase 3
    Registry statusWithdrawn

  • Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid)

    NCT06180057 · start 2022-06-12

    Registered record
    Registry ID
    NCT06180057
    Conditions
    Cerebrotendinous Xanthomatoses
    Interventions
    Chenodeoxycholic acid; Chenodeoxycholic acid leadiant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-12
    Completion
    2022-08-15
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebrotendinous Xanthomatoses
    InterventionChenodeoxycholic acid; Chenodeoxycholic acid leadiant
    PhasePhase 1
    Registry statusCompleted

  • Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition

    NCT04640571 · start 2021-04-01

    Registered record
    Registry ID
    NCT04640571
    Conditions
    Bile Salt Export Pump (BSEP) Transporter; Polysorbate 80
    Interventions
    pravastatin and chenodeoxycholic acid, after metformin and placebo; valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-04-01
    Completion
    2021-11-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBile Salt Export Pump (BSEP) Transporter; Polysorbate 80
    Interventionpravastatin and chenodeoxycholic acid, after metformin and placebo; valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
    PhasePhase 4
    Registry statusCompleted

  • Intravenous Infusion of CAP-1002 in Patients With COVID-19

    NCT04623671 · start 2020-11-15

    Registered record
    Registry ID
    NCT04623671
    Conditions
    Covid19
    Interventions
    CAP-1002; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-11-15
    Completion
    2022-02-04
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionCAP-1002; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

    NCT04270682 · start 2020-01-31

    Registered record
    Registry ID
    NCT04270682
    Conditions
    CTX
    Interventions
    Blinded CDCA 250 mg TID; Placebo; Open-Label CDCA 250 mg TID; Rescue Medication CDCA 250 mg TID; CDCA Weight-Based Dose TID
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-01-31
    Completion
    2023-10-04
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCTX
    InterventionBlinded CDCA 250 mg TID; Placebo; Open-Label CDCA 250 mg TID; Rescue Medication CDCA 250 mg TID +1 more
    PhasePhase 3
    Registry statusCompleted

  • A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

    NCT03406780 · start 2018-04-04

    Registered record
    Registry ID
    NCT03406780
    Conditions
    Muscular Dystrophies; Muscular Dystrophy, Duchenne; Muscular Disorders, Atrophic; Muscular Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn
    Interventions
    CAP-1002; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-04-04
    Completion
    2020-03-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMuscular Dystrophies; Muscular Dystrophy, Duchenne; Muscular Disorders, Atrophic; Muscular Diseases +4 more
    InterventionCAP-1002; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy

    NCT03168555 · start 2017-06-22

    Registered record
    Registry ID
    NCT03168555
    Conditions
    Bile Acid Malabsorption; Cholelithiasis
    Interventions
    chenodeoxycholic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-06-22
    Completion
    2019-05-15
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBile Acid Malabsorption; Cholelithiasis
    Interventionchenodeoxycholic acid
    PhasePhase 4
    Registry statusCompleted

  • Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea

    NCT03059537 · start 2017-03-13

    Registered record
    Registry ID
    NCT03059537
    Conditions
    Bile Acid Malabsorption
    Interventions
    Oral chenodeoxycholic acid stimulation
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-03-13
    Completion
    2017-11-27
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBile Acid Malabsorption
    InterventionOral chenodeoxycholic acid stimulation
    PhasePhase 4
    Registry statusCompleted

  • Infant Fecal Insult Study

    NCT02979210 · start 2016-11

    Registered record
    Registry ID
    NCT02979210
    Conditions
    Dermatitis
    Interventions
    Artificial Fecal Insult; Phosphate Buffered Saline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-11
    Completion
    2017-02-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis
    InterventionArtificial Fecal Insult; Phosphate Buffered Saline
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass

    NCT02952963 · start 2016-10

    Registered record
    Registry ID
    NCT02952963
    Conditions
    Severe Obesity
    Interventions
    Chenodeoxycholic Acid; Colesevelam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-10
    Completion
    2020-11
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Obesity
    InterventionChenodeoxycholic Acid; Colesevelam
    PhasePhase 4
    Registry statusCompleted

  • Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass

    NCT02876484 · start 2016-06

    Registered record
    Registry ID
    NCT02876484
    Conditions
    Severe Obesity
    Interventions
    Colesevelam; Chenodeoxycholic Acid; Water
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-06
    Completion
    2020-11
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Obesity
    InterventionColesevelam; Chenodeoxycholic Acid; Water
    PhasePhase 4
    Registry statusCompleted

  • Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5

    NCT02314208 · start 2015-01-08

    Registered record
    Registry ID
    NCT02314208
    Conditions
    Spastic Paraplegia, Hereditary
    Interventions
    Xenbilox; Resveratrol; Tahor
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-01-08
    Completion
    2018-01-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpastic Paraplegia, Hereditary
    InterventionXenbilox; Resveratrol; Tahor
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)

    NCT05499026 · start 2014-12-09

    Registered record
    Registry ID
    NCT05499026
    Conditions
    Cerebrotendinous Xanthomatoses
    Interventions
    Chenodeoxycholic Acid
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-12-09
    Completion
    2015-06-03
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebrotendinous Xanthomatoses
    InterventionChenodeoxycholic Acid
    PhaseNot recorded
    Registry statusCompleted

  • Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass

    NCT02340247 · start 2014-11

    Registered record
    Registry ID
    NCT02340247
    Conditions
    Severe Obesity
    Interventions
    Water; Ursodeoxycholic Acid; Chenodeoxycholic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-11
    Completion
    Not recorded
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Obesity
    InterventionWater; Ursodeoxycholic Acid; Chenodeoxycholic Acid
    PhasePhase 4
    Registry statusCompleted